Reversal of γ-Radiation-Induced Leukemogenesis in Mice by Immunomodulation with Thiabendazole and Dinitrofluorobenzene

• Published in: JNCI : Journal of the National Cancer Institute 1985-04, Vol.74 (4), p.811-815
• Main Authors: Eigebaly, Salwa A., Barton, Randall, Forouhar, Faripour
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic agents; Biological and medical sciences; Dinitrofluorobenzene - administration & dosage; Dinitrofluorobenzene - therapeutic use; Drug Therapy, Combination; Gamma Rays; General aspects; Immunotherapy; Leukemia, Radiation-Induced - chemically induced; Leukemia, Radiation-Induced - immunology; Leukemia, Radiation-Induced - prevention & control; Longevity - drug effects; Lymphoma - etiology; Lymphoma - immunology; Lymphoma - prevention & control; Male; Medical sciences; Mice; Mice, Inbred C57BL; Nitrobenzenes - administration & dosage; Organ Size - drug effects; Pharmacology. Drug treatments; T-Lymphocytes - drug effects; T-Lymphocytes - radiation effects; Thiabendazole - administration & dosage; Thiabendazole - therapeutic use; Thymus Gland - drug effects
• ISSN: 0027-8874; 1460-2105
• DOI: 10.1093/jnci/74.4.811

The effect of thiabendazole (TBZ) and dinitrofluorobenzene (DNFB) on radiation-induced leukemogenesis was investigated in the C57BL/6 mouse model. Administration of TBZ-DNFB during, post, or during and post irradiation successfully blocked leukemogenesis, as indicated by the absence of leukemia blast cells in thymus and peripheral blood, as well as prevented thymic lymphoma. TBZ-DNFB treatment prevented the development of leukemia when studies were terminated both after 7 months of last irradiation (disease fully developed) and after 5 months of last irradiation (disease in the process of development). This TBZ-DNFB treatment also resulted in a significant increase in survival.